Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL13735171 | 0.96 | PNMT (0.31) | PNMT | |
| SCHEMBL13085377 | 0.79 | — | — | |
| SCHEMBL1903771 | 0.78 | PNMT (0.40) | PNMT | |
| Hydrochloric Acid SCHEMBL19747006 | 0.76 | — | — | |
| Hydrochloric Acid SCHEMBL13733142 | 0.76 | PKM (0.37) | PKM | |
| Hydrochloric Acid SCHEMBL2875147 | 0.74 | PNMT (0.38) | PNMT | |
| SCHEMBL20221206 | 0.67 | PKM (0.40) | PKM | |
| SCHEMBL19850684 | 0.67 | PNMT (0.35) | PNMT | |
| SCHEMBL319529 | 0.65 | — | — | |
| SCHEMBL16039063 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552787-B2 | Quinazoline compound | MEDSHINE DISCOVERY INC. (CN) | 2026-02-17 | — | — | US | disclosed |
| US-20250361399-A1 | FLUORESCENT DYES WITH LARGE STOKES SHIFT | ROCHE MOLECULAR SYSTEMS INC (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4547757-A2 | FLUORESCENT DYES WITH LARGE STOKES SHIFT | F. Hoffmann-La Roche AG (CH) | 2025-05-07 | — | — | EP | disclosed |
| EP-3971177-B1 | AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | NOVARTIS AG (CH) | 2024-06-26 | — | — | EP | disclosed |
| CN-113453764-B | 7H-pyrrolo [2,3-d ] pyrimidin-4-amine derivatives | 大鹏药品工业株式会社 | 2024-04-16 | — | — | CN | disclosed |
| EP-3583105-B1 | PYRROLO [1,2-B]PYRIDAZINE DERIVATIVES | GILEAD SCIENCES INC (US) | 2024-02-07 | — | — | EP | disclosed |
| WO-2024002924-A2 | FLUORESCENT DYES WITH LARGE STOKES SHIFT | F. HOFFMANN-LA ROCHE AG (CH) | 2024-01-04 | — | — | WO | disclosed |
| US-11786534-B2 | Substituted pyrrolo[2,3-d]pyrimidines as EGFR inhibitors | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-10-17 | — | — | US | disclosed |
| US-20230265090-A1 | QUINAZOLINE COMPOUND | MEDSHINE DISCOVERY INC. (CN) | 2023-08-24 | — | — | US | disclosed |
| US-20230265090-A1 | QUINAZOLINE COMPOUND | MEDSHINE DISCOVERY INC. (CN) | 2023-08-24 | — | — | US | disclosed |
| WO-2015019325-A1 | BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-02-12 | — | — | WO | disclosed |
| US-20140296233-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | SANOFI (FR) | 2014-10-02 | — | — | US | disclosed |
| WO-2014144737-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-8507493-B2 | Amide and amidine derivatives and uses thereof | ABBVIE INC. (US) | 2013-08-13 | — | — | US | disclosed |
| WO-2010123838-A2 | NOVEL AMIDE AND AMIDINE DERIVATIVES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-10-28 | — | — | WO | disclosed |
| EP-2243479-A2 | Novel amide and amidine derivates and uses thereof | Abbott Laboratories (US) | 2010-10-27 | — | — | EP | disclosed |
| US-20100267738-A1 | NOVEL AMIDE AND AMIDINE DERIVATIVES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-10-21 | — | — | US | disclosed |
| US-7560569-B2 | (2S,4S)-1-[[(4-carbamoylbicyclo[2.2.2]oct-1-yl)amino]acetyl]-4-fluoropyrrolidine-2-carbonitrile, for treating type II diabetes; increase glucagon-like peptide activity | KYORIN PHARMACEUTICAL CO., LTD (JP) | 2009-07-14 | — | — | US | disclosed |
| US-20070265320-A1 | Bicycloamide Derivative | KYORIN PHARMACEUTICAL CO., LTD (JP) | 2007-11-15 | — | — | US | disclosed |
| EP-1717225-A1 | BICYCLIC AMIDE DERIVATIVES | Kyorin Pharmaceutical Co., Ltd. (JP) | 2006-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267738-A1 | NOVEL AMIDE AND AMIDINE DERIVATIVES AND USES THEREOF | HSD11B2, HSD11B1, HSD17B2 | PNMT 1078/4885PKM 1857/4885 |
| US-20230265090-A1 | QUINAZOLINE COMPOUND | ABCG2, CYP3A7, ABL1 | PNMT 2809/4885PKM 2336/4885 |
| US-20140296233-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | PNMT 2016/4885PKM 2625/4885 |
| US-20070265320-A1 | Bicycloamide Derivative | DPP4, DPP7, DPP9 | PNMT 3480/4885PKM 1468/4885 |
| US-12552787-B2 | Quinazoline compound | SLC9A3, CLIC1, NHERF1 | PNMT 3880/4885PKM 2711/4885 |
| US-11786534-B2 | Substituted pyrrolo[2,3-d]pyrimidines as EGFR inhibitors | EGFR, ERBB2, ERBB3 | PNMT 3277/4885PKM 2853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.